查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1993176

Butorphanol市场：按给药途径、分销管道、应用和最终用户分類的全球市场预测，2026-2032年

Butorphanol Market by Route Of Administration, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，Butorphanol市值将达到 2.9611 亿美元，到 2026 年将成长至 3.1157 亿美元，到 2032 年将达到 4.0017 亿美元，复合年增长率为 4.39%。

主要市场统计数据
基准年 2025 2.9611亿美元
预计年份：2026年 3.1157亿美元
预测年份：2032年 4.017亿美元
复合年增长率 (%) 4.39%

Butorphanol的药理作用和製剂考虑的简明临床框架：阐明其在现代镇痛策略中的地位。

Butorphanol在镇痛治疗中占有独特的地位，它既是阿片受体促效剂又是拮抗剂，常用于临床治疗急性中重度疼痛。其动态特性结合了κ阿片受体激动作用和部分μ阿片受体拮抗作用，与完全μ受体促效剂相比，在疗效和安全性之间实现了独特的平衡。临床医师在权衡镇痛效果与呼吸抑制及其他μ阿片受体介导的副作用时，尤其在分娩和手术全期护理等情况下，会特别重视这些特性。

监管重点、供应链现代化和以病人为中心的照护模式如何融合，从而重新定义止痛药的临床和商业性方法？

包括Butorphanol在内的止痛药领域正经历变革，这主要得益于监管力度加大、以病人为中心的照护模式以及供应链现代化。随着人们对鸦片类药物合理使用和替代性疼痛管理途径的关注度不断提高，多方面治疗方法正在加速，包括对某些适应症中具有混合促效剂-拮抗剂特性的药物进行重新评估。同时，临床上对非口服给药方式的需求日益增长，促使临床医生和采购团队重新考虑在其製剂中加入註射剂和鼻内给药方案，从而在住院和门诊环境中实现快速、剂量可控的镇痛。

评估到 2025 年的最新关税调整如何重塑整个镇痛药价值链的筹资策略、供应弹性工作和采购决策。

美国在2025年前实施和调整关税，对与Butorphanol相关的医药价值链施加了多方面的压力。关税导致进口原料药和特殊辅料成本增加，加剧了采购的复杂性，并可能促使生产商重新考虑其筹资策略。为此，一些生产商正在寻求供应商多元化、透过合约进行风险对冲，并与国内契约製造组织（CMO）合作，以降低进口关税和物流中断的风险。

以细分市场为重点的临床和商业性见解，整合给药途径、治疗应用、最终用户需求和分销管道，以提供可操作的知识。

细分市场分析揭示了Butorphanol在临床应用、采购管道和患者获取方面的显着模式。根据给药途径，相关人员对注射剂、鼻腔剂和口服剂型进行比较和评估。注射剂途径进一步细分为肌肉注射和静脉注射，每种途径都适用于特定的临床工作流程，例如术前术后或急诊医疗环境中的快速剂量调整。就适应症而言，布托啡诺在慢性疼痛管理、分娩疼痛和手术疼痛方面的治疗定位各不相同，需要製定个人化的临床通讯协定并对医生进行培训，以确保最佳的治疗效果。

美洲、欧洲、中东、非洲和亚太地区的区域趋势影响着镇痛治疗的监管管道、临床引入和供应链设计。

区域趋势正显着影响Butorphanol的法规结构、临床实务模式和供应链结构。在美洲，关于阿片类药物管理的政策讨论以及健全的医院急性护理网络正在推动布托啡诺在手术全期和分娩过程中的广泛应用。同时，筹资策略日益重视供应的连续性和对不断变化的监管要求的遵守。该地区的生产商和经销商正在协调宣传活动和配方支持，以体现这些机构的优先事项和严格的法律规范。

製造商、专业製药公司和合约合作伙伴之间的竞争定位和策略联盟的主题决定了供应可靠性和临床渗透率。

製药公司、专业製药公司和合约研发生产机构 (CDMO) 之间的竞争与合作动态在Butorphanol的研发、生产和分销中发挥核心作用。大型非专利生产商利用规模经济和一体化供应链来支援稳定的生产和广泛的分销。另一方面，专业製药公司则专注于製剂创新、特定适应症和医疗专业人员培训，以实现产品差异化。契约製造和 CDMO 透过助力产能扩张、确保符合不断发展的药品生产品质管理规范 (GMP) 以及快速转移本地生产所需的技术，发挥日益重要的战略作用。

产业领导者可以实施的切实可行的策略措施，以加强镇痛产品的供应韧性、临床引入和分销管道协调。

在瞬息万变的止痛药市场中，产业领导者可以采取多项切实可行的措施来提升临床应用率、供应链韧性和商业性绩效。首先，他们应优先进行有针对性的临床教育，并与医疗机构的相关人员进行沟通，重点强调混合促效剂-拮抗剂製剂的临床优势及其在多方面疼痛管理通讯协定中的作用。其次，他们应加快供应商多元化，并考虑将关键生产流程外包至近岸地区，以降低进口关税和物流衝击带来的风险，同时投资于合规和品管体系，以确保符合监管要求。

透明且符合伦理的调查方法，结合专家访谈、监管审查和三角资料检验，检验临床和供应链见解。

本研究整合了来自一手和二手调查的讯息，包括对临床专家、采购负责人和生产主管的结构化访谈，检验实际情况与临床细微差别之间的微妙之处。二手调查纳入了监管文件、同行评审的临床文献、药物安全监测报告和公共公告，以阐明临床模式和政策影响的背景。数据三角验证确保了从专家讨论中获得的定性见解与已记录的监管更新、临床指南和可观察到的供应链趋势相一致。

明确的整合强调临床定位、供应弹性和实证策略共同决定镇痛方案在医疗保健服务中的未来角色。

总之，Butorphanol仍是一种重要的临床止痛药物，其效用取决于其药理特性、给药途径以及疼痛管理决策的背景。监管力度加大、临床范式向多方面镇痛的转变以及到2025年贸易政策的变化，都凸显了适应性采购、有针对性的临床合作和严格的安全监测的必要性。将这些要求纳入采购、製剂策略和临床医生参与的相关人员，将更有利于维持药物的可及性并展现其治疗价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章Butorphanol市场：依给药途径划分

  • 注射
    • 肌肉内注射
    • 静脉注射
  • 鼻喷雾
  • 药片

第九章Butorphanol市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十章Butorphanol市场：依应用

  • 慢性疼痛管理
  • 分娩疼痛管理
  • 手术期间的疼痛管理

第十一章Butorphanol市场：依最终用户划分

  • 门诊部
  • 家庭医疗保健
  • 医院

第十二章Butorphanol市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章Butorphanol市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章Butorphanol市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国Butorphanol市场

第十六章：中国的Butorphanol市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Animedica
  • Apotex Inc.
  • Apothecon Pharmaceuticals
  • Athanas Enterprise Private Limited
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Dechra Pharmaceuticals
  • Faunapharma
  • Fresenius Kabi AG
  • Hikal Limited
  • Hikma Pharmaceuticals PLC
  • Merck KGaA
  • Mylan NV
  • Novex Pharma
  • Pfizer Inc.
  • Richter Pharma AG
  • Sagent Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanochemia Pharmazeutika
  • Selectavet
  • Taj Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Troy Laboratories NZ
  • Zoetis Inc.
Product Code: MRR-1A1A064C0322

The Butorphanol Market was valued at USD 296.11 million in 2025 and is projected to grow to USD 311.57 million in 2026, with a CAGR of 4.39%, reaching USD 400.17 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 296.11 million
Estimated Year [2026] USD 311.57 million
Forecast Year [2032] USD 400.17 million
CAGR (%) 4.39%

A concise clinical framing of butorphanol's pharmacological role and prescribing considerations that illuminate its place in contemporary analgesic strategies

Butorphanol occupies a distinct niche within analgesic pharmacotherapy as a mixed opioid agonist-antagonist that is frequently employed for acute moderate to severe pain management in clinical settings. Its pharmacodynamic profile, which combines kappa-opioid receptor agonism with partial mu-opioid receptor antagonism, gives it unique efficacy and safety trade-offs compared with full mu agonists. Clinicians value these characteristics when balancing analgesia against respiratory depression and other mu-mediated adverse effects, particularly in settings such as labor and perioperative care.

Clinical practice and formulary committees evaluate butorphanol through multiple lenses: route of administration flexibility, rapid onset in injectable forms, the convenience of intranasal delivery in outpatient and ambulatory contexts, and tolerability in diverse patient populations. Regulatory pathways and hospital protocols influence how healthcare providers integrate butorphanol into multimodal analgesia strategies, while pharmacovigilance continues to refine risk mitigation for opioid-related events. Amid evolving pain management paradigms and heightened scrutiny of opioid prescribing, butorphanol's pharmacological attributes sustain its role in targeted therapeutic scenarios.

How regulatory focus, supply chain modernization, and patient-centric care models are converging to redefine clinical and commercial approaches to analgesics

The landscape for analgesics, including butorphanol, is undergoing transformative shifts driven by regulatory scrutiny, patient-centric care models, and supply chain modernization. Increasing emphasis on opioid stewardship and alternative pain pathways has accelerated adoption of multimodal regimens where agents with mixed agonist-antagonist profiles are reconsidered for specific indications. Concurrently, clinical demand for non-oral delivery has grown, prompting clinicians and procurement teams to reassess formulary placement for injectable and intranasal therapies that permit rapid, titratable analgesia in both inpatient and outpatient settings.

Supply chain dynamics are also changing; manufacturers and healthcare systems are investing in redundancy, nearshoring of critical intermediates, and tighter quality controls to safeguard continuity. These shifts are complemented by digital health innovations that enable remote patient monitoring and telehealth-facilitated prescribing, which influence the roles of ambulatory care centers, home healthcare providers, and hospital systems in delivering analgesic therapy. Taken together, these forces are reshaping how butorphanol is positioned clinically and commercially, creating opportunities for differentiated formulations and targeted educational outreach to prescribers.

Assessment of how recent tariff policy adjustments through 2025 have reshaped sourcing strategies, supply resilience efforts, and procurement decision-making across the analgesic value chain

The imposition and recalibration of tariffs in the United States through 2025 have exerted multi-dimensional pressure on the pharmaceutical value chain relevant to butorphanol. Tariff-driven increases in the cost of imported active pharmaceutical ingredients and specialty excipients can amplify procurement complexity and incentivize manufacturers to reassess sourcing strategies. In response, some producers have pursued supplier diversification, contractual hedging, and partnerships with domestic contract manufacturing organizations to lessen vulnerability to import levies and logistical disruption.

These adjustments have downstream implications for formulary committees and healthcare purchasers who must reconcile pricing dynamics with commitments to uninterrupted clinical supply. At the same time, tariff changes intersect with regulatory and quality assurance priorities; organizations that accelerate localization of critical manufacturing steps often face initial capital and compliance investments that lengthen lead times but strengthen long-term resilience. As a result, strategic players emphasize supply transparency, batch-level traceability, and collaborative forecasting to mitigate the operational impacts of tariff policy shifts while maintaining stewardship of therapeutic availability.

Segment-focused clinical and commercial implications that align administration routes, therapeutic applications, end-user needs, and distribution channels into actionable insights

Insight into segmentation reveals meaningful patterns in clinical use, procurement pathways, and patient access for butorphanol. Based on route of administration, stakeholders evaluate injectable options versus intranasal delivery and oral formulations; the injection pathway is further differentiated by intramuscular and intravenous modalities, each aligned to specific clinical workflows such as rapid titration in perioperative or emergency settings. Based on application, therapeutic positioning varies across chronic pain management, labor pain, and surgical pain, prompting tailored clinical protocols and education for prescribers to ensure optimal outcomes.

Based on end user, adoption and utilization differ among ambulatory care centers, home healthcare services, and hospitals, with each setting presenting distinct procurement cycles, storage requirements, and administration competencies. Based on distribution channel, supply continuity is managed through hospital pharmacies, online pharmacies, and retail pharmacies, which collectively shape patient access and the logistics of replenishment. Integrating these segmentation lenses helps stakeholders align development priorities, clinical education, and commercial outreach to the settings and administration routes where butorphanol demonstrates the strongest clinical fit.

Regional dynamics shaping regulatory pathways, clinical adoption, and supply chain design across the Americas, EMEA, and Asia-Pacific for analgesic therapies

Regional dynamics exert a pronounced influence on regulatory frameworks, clinical practice patterns, and supply chain architecture for butorphanol. In the Americas, policy debates around opioid stewardship and robust hospital-based acute care networks drive concentrated use in perioperative and labor contexts, while procurement strategies increasingly emphasize supply continuity and compliance with evolving controlled-substance regulations. Manufacturers and distributors in this region calibrate educational outreach and formulary support to reflect these institutional priorities and rigorous regulatory oversight.

Across Europe, the Middle East, and Africa, heterogeneous regulatory environments and diverse healthcare infrastructures create differentiated adoption pathways; some jurisdictions prioritize community-based pain management and outpatient access, whereas others rely heavily on centralized hospital procurement and strict narcotics controls. These variations necessitate nuanced regulatory submissions and localized pharmacovigilance frameworks. In the Asia-Pacific region, rapid expansion of ambulatory care, growing home healthcare delivery models, and investments in localized manufacturing capacity shape demand dynamics, with regional players increasingly focused on scalability, cost-efficiency, and alignment with public health guidelines. Collectively, these regional currents inform market entry strategies, distribution partnerships, and clinical engagement models.

Competitive positioning and strategic collaboration themes among manufacturers, specialty firms, and contract partners that determine supply reliability and clinical uptake

Competitive and collaborative forces among manufacturers, specialty pharmaceutical firms, and contract development and manufacturing organizations are central to how butorphanol is developed, produced, and distributed. Large generic manufacturers leverage scale and integrated supply chains to support steady production and broad distribution, whereas specialty companies focus on formulation innovation, niche indications, and provider education to differentiate products. Contract manufacturers and CDMOs play an increasingly strategic role by enabling capacity expansion, compliance with evolving good manufacturing practices, and rapid technology transfer for localized production.

Strategic collaborations between commercial teams and clinical educators drive adoption in targeted settings, while supply chain partnerships emphasize redundancy and regulatory alignment. Companies are also investing in pharmacovigilance infrastructure, real-world evidence generation, and lifecycle management to sustain product relevance amid heightened scrutiny of opioid therapies. Taken together, these dynamics highlight the importance of operational excellence, clinical engagement, and adaptive commercial models for stakeholders involved in the butorphanol value chain.

Practical strategic measures that industry leaders can implement to fortify supply resilience, clinical adoption, and channel alignment for analgesic products

Industry leaders can take several practical, actionable steps to strengthen clinical adoption, supply resilience, and commercial performance in the evolving analgesic environment. First, prioritize targeted clinical education and institution-level stakeholder engagement that highlights where mixed agonist-antagonist agents can offer clinical advantages and how they fit within multimodal pain protocols. Second, accelerate supplier diversification and consider nearshoring key manufacturing steps to reduce exposure to import tariffs and logistics shocks while investing in compliance and quality systems to maintain regulatory alignment.

Third, tailor distribution strategies to the operational realities of ambulatory care centers, home healthcare providers, and hospitals by optimizing channel partnerships with hospital pharmacies, online dispensaries, and retail outlets to preserve access. Fourth, invest in pharmacovigilance and real-world evidence programs that substantiate safety and efficacy profiles in the settings most relevant to product use, thereby facilitating informed formulary decisions. Finally, leverage collaborative contracting and shared-risk procurement models with healthcare systems to build long-term partnerships focused on continuity of supply, cost predictability, and clinical outcomes.

A transparent and ethically grounded research methodology combining expert interviews, regulatory review, and data triangulation to validate clinical and supply insights

This research synthesizes primary and secondary information streams, including structured interviews with clinical experts, procurement officers, and manufacturing executives to validate operational realities and clinical nuances. Secondary research incorporated regulatory filings, peer-reviewed clinical literature, pharmacovigilance reports, and public policy announcements to contextualize practice patterns and policy impacts. Data triangulation ensured that qualitative insights from expert discussions were cross-checked against documented regulatory updates, clinical guidance, and observable supply chain developments.

Methodological rigor was maintained through transparent inclusion criteria for expert selection, standardized interview guides, and a replicable approach to synthesizing disparate evidence. Limitations are acknowledged where public data is sparse or where practice variability across jurisdictions limits generalizability; consequently, recommendations emphasize strategic flexibility and the need for localized validation. Ethical standards governed interactions with clinical informants, and proprietary data sources were treated under non-disclosure protocols to protect commercial sensitivity while preserving analytical integrity.

A conclusive synthesis emphasizing how clinical positioning, supply resilience, and evidence strategies together determine the future role of analgesic options in care delivery

In conclusion, butorphanol remains a clinically relevant analgesic option whose utility is shaped by its pharmacological profile, administration routes, and the settings in which pain management decisions are made. The confluence of regulatory scrutiny, shifting clinical paradigms toward multimodal analgesia, and changes in trade policy through 2025 underscores the need for adaptive sourcing, targeted clinical engagement, and rigorous safety monitoring. Stakeholders that integrate these imperatives into procurement, formulation strategy, and clinician outreach will be better positioned to sustain access and demonstrate therapeutic value.

Looking forward, success will favor organizations that combine operational resilience with nuanced clinical messaging and evidence generation. Emphasis on partnership models with healthcare systems, investments in localized manufacturing capabilities where feasible, and proactive pharmacovigilance will help balance stewardship objectives with patient access. Ultimately, a measured, evidence-based approach to product positioning and supply strategy will maximize the ability to meet clinical needs while navigating an increasingly complex regulatory and commercial landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Butorphanol Market, by Route Of Administration

  • 8.1. Injection
    • 8.1.1. Intramuscular Injection
    • 8.1.2. Intravenous Injection
  • 8.2. Nasal Spray
  • 8.3. Tablet

9. Butorphanol Market, by Distribution Channel

  • 9.1. Hospital Pharmacy
  • 9.2. Online Pharmacy
  • 9.3. Retail Pharmacy

10. Butorphanol Market, by Application

  • 10.1. Chronic Pain Management
  • 10.2. Labor Pain Management
  • 10.3. Surgical Pain Management

11. Butorphanol Market, by End User

  • 11.1. Ambulatory Care Center
  • 11.2. Home Healthcare
  • 11.3. Hospital

12. Butorphanol Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Butorphanol Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Butorphanol Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Butorphanol Market

16. China Butorphanol Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Animedica
  • 17.6. Animedica
  • 17.7. Apotex Inc.
  • 17.8. Apothecon Pharmaceuticals
  • 17.9. Apothecon Pharmaceuticals
  • 17.10. Athanas Enterprise Private Limited
  • 17.11. B. Braun Melsungen AG
  • 17.12. Baxter International Inc.
  • 17.13. Boehringer Ingelheim
  • 17.14. Boehringer Ingelheim
  • 17.15. Bristol Myers Squibb
  • 17.16. Bristol Myers Squibb
  • 17.17. Dechra Pharmaceuticals
  • 17.18. Dechra Pharmaceuticals
  • 17.19. Faunapharma
  • 17.20. Faunapharma
  • 17.21. Fresenius Kabi AG
  • 17.22. Hikal Limited
  • 17.23. Hikal Limited
  • 17.24. Hikma Pharmaceuticals PLC
  • 17.25. Merck KGaA
  • 17.26. Merck KGaA
  • 17.27. Mylan N.V.
  • 17.28. Novex Pharma
  • 17.29. Novex Pharma
  • 17.30. Pfizer Inc.
  • 17.31. Richter Pharma AG
  • 17.32. Richter Pharma AG
  • 17.33. Sagent Pharmaceuticals, Inc.
  • 17.34. Sandoz International GmbH
  • 17.35. Sanochemia Pharmazeutika
  • 17.36. Sanochemia Pharmazeutika
  • 17.37. Selectavet
  • 17.38. Selectavet
  • 17.39. Taj Pharmaceuticals Ltd.
  • 17.40. Taj Pharmaceuticals Ltd.
  • 17.41. Teva Pharmaceutical Industries Ltd.
  • 17.42. Troy Laboratories NZ
  • 17.43. Troy Laboratories NZ
  • 17.44. Zoetis Inc.
  • 17.45. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BUTORPHANOL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BUTORPHANOL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BUTORPHANOL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BUTORPHANOL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BUTORPHANOL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BUTORPHANOL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BUTORPHANOL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BUTORPHANOL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BUTORPHANOL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BUTORPHANOL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BUTORPHANOL MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BUTORPHANOL MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BUTORPHANOL MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BUTORPHANOL MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BUTORPHANOL MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BUTORPHANOL MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BUTORPHANOL MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BUTORPHANOL MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BUTORPHANOL MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BUTORPHANOL MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BUTORPHANOL MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BUTORPHANOL MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BUTORPHANOL MARKET SIZE, BY LABOR PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BUTORPHANOL MARKET SIZE, BY LABOR PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BUTORPHANOL MARKET SIZE, BY LABOR PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BUTORPHANOL MARKET SIZE, BY SURGICAL PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BUTORPHANOL MARKET SIZE, BY SURGICAL PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BUTORPHANOL MARKET SIZE, BY SURGICAL PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BUTORPHANOL MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BUTORPHANOL MARKET SIZE, BY AMBULATORY CARE CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BUTORPHANOL MARKET SIZE, BY AMBULATORY CARE CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BUTORPHANOL MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BUTORPHANOL MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BUTORPHANOL MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BUTORPHANOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS BUTORPHANOL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BUTORPHANOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GCC BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. GCC BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 108. GCC BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. GCC BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. GCC BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. G7 BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 126. G7 BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. G7 BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. G7 BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. NATO BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 132. NATO BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. NATO BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NATO BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES BUTORPHANOL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA BUTORPHANOL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)